This topic covers the rules around drugs rather than a drug action: how drugs are named, how they are approved and classified, and how drugs with abuse potential are controlled. These rules exist to prevent confusion, duplication, diversion, and harm.
Three names for every drug
| Name | Description | Example |
|---|
| Chemical name | Describes the molecular structure; rarely used clinically | N-(4-hydroxyphenyl)acetamide |
| Generic (nonproprietary) name | One official name for the active ingredient, assigned by national naming bodies and the WHO International Nonproprietary Names (INN) program; written in lowercase | acetaminophen (US) / paracetamol (INN) |
| Brand (trade, proprietary) name | Owned by a manufacturer; capitalized, often with ® or ™; one generic drug may have many brands | Various brands worldwide |
Why generic names matter
- One active ingredient = one generic name, so staff and clients can recognize duplicates (e.g., acetaminophen in several cold, sleep, and pain combination products → liver injury)
- Generic names are used in drug references, exams, and most international settings; brand names differ between countries
- Drug classes are recognized by shared generic name stems: -olol (beta blockers), -pril (ACE inhibitors), -sartan (ARBs), -statin (HMG-CoA reductase inhibitors), -prazole (proton pump inhibitors), -azepam / -azolam (benzodiazepines), -mab (monoclonal antibodies), -floxacin (fluoroquinolones), -parin (heparins), -xaban (factor Xa inhibitors)
US and international (INN/British) names that differ
| US name | International / other name |
|---|
| Acetaminophen | Paracetamol |
| Albuterol | Salbutamol |
| Epinephrine | Adrenaline |
| Norepinephrine | Noradrenaline |
| Meperidine | Pethidine |
| Glyburide | Glibenclamide |
| Isoproterenol | Isoprenaline |
| Cyclosporine | Ciclosporin |
Classification
- Therapeutic class — by use (antihypertensive, anticoagulant, analgesic)
- Pharmacologic class — by mechanism (beta blocker, ACE inhibitor, opioid agonist)
- Prototype drug — the model drug of a class used to learn its shared features (e.g., morphine for opioids, propranolol for beta blockers)
- Prescription (Rx) vs over-the-counter (OTC) — OTC drugs are judged safe for self-care with label directions, but still cause interactions and overdose
Drug approval and safety surveillance (general model)
| Stage | Purpose |
|---|
| Preclinical (laboratory, animal) | Toxicity, pharmacology |
| Phase I | Small group, usually healthy volunteers — safety, dosing, pharmacokinetics |
| Phase II | Clients with the condition — effectiveness, short-term adverse effects |
| Phase III | Large controlled trials — confirm benefit and adverse effects; basis for approval |
| Phase IV (post-marketing surveillance) | Rare and long-term effects found after wide use — adverse drug reaction reports from nurses and others feed this stage |
Generic equivalence. An approved generic product has the same active ingredient, strength, dosage form, and route as the original and is shown to be bioequivalent. Inactive ingredients (fillers, dyes, lactose, preservatives) can differ — relevant to allergies and intolerances. For narrow therapeutic index drugs (levothyroxine, antiepileptics, warfarin, lithium, tacrolimus), switching products is acceptable but warrants closer monitoring of levels and response.
Safety warnings and risk-management programs
- The most serious risks are highlighted prominently in drug labeling (e.g., a boxed warning in the US)
- Some drugs are available only under restricted programs requiring prescriber, pharmacy, or client enrollment, testing, or education (e.g., isotretinoin pregnancy prevention)
Controlled substances — the concept
Drugs with potential for misuse, dependence, and diversion are placed in schedules (categories) by law. Schedules are based on:
- Potential for abuse and dependence
- Accepted medical use
- Safety under medical supervision
Most countries follow the United Nations drug control conventions (1961 Single Convention on Narcotic Drugs; 1971 Convention on Psychotropic Substances), so the same groups are controlled worldwide, though the schedule names and numbers differ by country.
| Group | Typical examples |
|---|
| Opioids | Morphine, fentanyl, oxycodone, hydromorphone, methadone, meperidine/pethidine, codeine, tramadol, buprenorphine |
| Stimulants | Amphetamine, methylphenidate, cocaine (topical anesthetic use) |
| Sedative-hypnotics | Benzodiazepines (diazepam, lorazepam, midazolam, alprazolam), zolpidem, phenobarbital |
| Others | Ketamine, anabolic steroids (testosterone), some antiepileptics (pregabalin) and cannabis-derived products, depending on country |
Risks linked to these regulatory areas:
- Duplicate therapy from brand/generic confusion (two acetaminophen-containing products; two benzodiazepines under different brand names)
- Look-alike, sound-alike names (hydroxyzine vs hydralazine; immediate-release vs extended-release oxycodone; hydromorphone vs morphine) → wrong drug or wrong dose
- Misuse, dependence, and diversion of controlled substances — by clients, families, or health workers
- Accidental poisoning of children and pets from unsecured or improperly discarded drugs
- Counterfeit or substandard drugs bought from unlicensed sources, including online sellers — may contain no drug, the wrong drug, or illicit fentanyl
General prescription rules (details vary by country and setting)
- A valid prescription or medication order contains: client identifiers, date, drug name (generic), strength, dosage form, dose, route, frequency, quantity, indication for PRN drugs, and the prescriber's signature and registration or license details
- Controlled substances have stricter rules: special prescriber registration or license, additional prescription details, limits on quantity and refills, and sometimes special prescription forms
- Nurses administer medications under orders; prescribing is limited to legally authorized prescribers (including advanced practice nurses where the law allows)
- Verbal and telephone orders only when necessary, with read-back; many facilities restrict verbal orders for controlled substances and chemotherapy
- Question any order that is unclear, incomplete, or unsafe before giving the drug
Listed in priority order.
- Give the right drug: confirm the generic name on every label; use tall-man lettering and separate storage for look-alike names; check for duplicate active ingredients
- Secure controlled substances
- Store in locked, access-controlled storage (automated dispensing cabinet or double-locked cabinet); keep keys and access codes personal — never share passwords or badges
- Remove only for the client and dose ordered, at the time of administration; document every dose removed
- Counts
- Count at change of shift (or per policy) by two authorized nurses — one counts, the other watches and checks the record
- Report any discrepancy immediately to the charge nurse or pharmacy and resolve it before either nurse leaves; follow the incident process
- Waste
- Partial doses and refused or contaminated doses are wasted in the presence of a second licensed witness, who co-signs the record at the time of waste
- Never pre-sign or sign for a waste you did not see; use approved waste containers
- Recognize diversion and impairment
- Warning signs in a colleague: frequent wastes or "dropped" doses, clients who report poor pain relief only on one nurse's shifts, frequent unexplained absences from the unit, arriving early or staying late without need, signs of impairment
- Report concerns to the supervisor following facility policy — this protects clients and is a professional duty; it is not optional
- Client's own controlled drugs brought from home: follow policy (send home with family or secure and count with pharmacy)
- Documentation: controlled substance records are legal documents; complete them accurately and promptly
- Learn the generic name of each medicine; check labels to avoid taking the same ingredient twice
- Buy medicines only from licensed pharmacies; avoid unverified online sellers
- Never share prescription drugs, especially opioids, sedatives, and stimulants — it is dangerous and illegal
- Store controlled drugs locked and count them; keep them away from children, visitors, and pets
- Disposal
- First choice: a drug take-back program or collection point
- If none is available: follow local rules; a small group of high-risk drugs (e.g., some opioids such as fentanyl patches) may be flushed where the national regulator permits it; most others can be mixed with an unappealing substance (used coffee grounds, dirt, cat litter), sealed in a bag, and put in household trash, with personal information removed from labels
- Fold used fentanyl patches in half with the sticky sides together before disposal
- Keep naloxone at home when prescribed high-dose opioids or when anyone in the home is at risk of opioid overdose
- Travel with controlled drugs in original labeled containers with a copy of the prescription; check destination country rules
| Situation | Response |
|---|
| Opioid overdose (pinpoint pupils, respiratory depression, unresponsiveness) | Airway and breathing; naloxone; repeat as needed; monitor for re-sedation |
| Illicit fentanyl and analogues | May need repeated naloxone doses; support ventilation |
| Benzodiazepine overdose | Supportive care; flumazenil only in selected cases (seizure risk in chronic users) |
| Stimulant toxicity | Agitation, hyperthermia, hypertension, tachycardia, seizures — cooling, benzodiazepines, supportive care |
| Opioid + benzodiazepine or alcohol | Synergistic respiratory depression — highest-risk combination |
| Wrong drug from name confusion | Assess the client first, notify the prescriber, treat, report |
Errors and discrepancies with controlled drugs are both safety events and legal matters; they must be reported, never concealed.
- Three names: chemical, generic, brand — use the generic name
- One generic, many brands; brand names differ between countries
- Know US/international pairs: acetaminophen/paracetamol, albuterol/salbutamol, epinephrine/adrenaline, meperidine/pethidine, glyburide/glibenclamide
- Name stems identify classes (-olol, -pril, -sartan, -statin, -prazole, -xaban)
- Generics are bioequivalent; inactive ingredients differ; monitor narrow therapeutic index drugs after switching
- Phase IV = post-marketing surveillance — report adverse reactions
- Controlled substance schedules reflect abuse potential, accepted medical use, and safety
- Count at shift change; resolve discrepancies before leaving; witnessed and co-signed waste
- Never share access codes; never co-sign a waste you did not witness
- Report suspected diversion or impairment
- Disposal: take-back first; otherwise follow local rules (flush only listed drugs; mix and seal others in trash)
Country Notes
United States
- The FDA approves drugs, generics (listed with therapeutic equivalence ratings in the Orange Book), labeling, boxed warnings, and REMS (Risk Evaluation and Mitigation Strategies). Examples: iPLEDGE for isotretinoin; the opioid analgesic REMS; the etonogestrel implant REMS for insertion and removal (from February 23, 2026). REMS can be removed when no longer needed — the clozapine REMS was eliminated in June 2025.
- The Controlled Substances Act (1970) is enforced by the DEA; prescribers of controlled substances need DEA registration.
| DEA schedule | Meaning | Examples |
|---|
| I | High abuse potential, no currently accepted medical use | Heroin, LSD, MDMA |
| II | High abuse potential, accepted medical use, severe dependence | Morphine, fentanyl, oxycodone, hydromorphone, methadone, meperidine, amphetamine, methylphenidate, cocaine |
| III | Moderate potential | Ketamine, buprenorphine, anabolic steroids, acetaminophen with codeine |
| IV | Lower potential | Benzodiazepines, zolpidem, tramadol, phenobarbital |
| V | Lowest potential | Codeine-containing cough preparations (limited amounts), pregabalin |
- Schedule II prescriptions cannot be refilled; Schedule III–IV prescriptions may be refilled up to 5 times within 6 months of issue.
- Marijuana: since April 28, 2026, marijuana in FDA-approved products and marijuana under a state medical marijuana license are in Schedule III; all other marijuana remains in Schedule I. Broader rescheduling was heard by a DEA administrative law judge in June–July 2026 and was still pending; the partial order faces court challenges but remains in effect. Check current status.
- Since 2023, a separate "X-waiver" is no longer needed to prescribe buprenorphine for opioid use disorder. Drug disposal follows FDA guidance (take-back first; FDA flush list only for listed drugs).
Philippines
- Generics Act of 1988 (RA 6675), amended by the Universally Accessible Cheaper and Quality Medicines Act of 2008 (RA 9502): generic names must be used in prescribing, dispensing, labeling, and procurement.
- The Food and Drug Administration Act of 2009 (RA 9711) renamed the Bureau of Food and Drugs (BFAD) as the FDA Philippines and strengthened its powers; the FDA registers drugs and monitors their safety.
- The Philippine Pharmacy Act (RA 10918, 2016): prescription drugs are dispensed by licensed pharmacists.
- The Comprehensive Dangerous Drugs Act of 2002 (RA 9165) governs dangerous drugs; the Dangerous Drugs Board sets policy and the Philippine Drug Enforcement Agency (PDEA) licenses and enforces. Physicians need a PDEA S2 license to prescribe dangerous drugs, which are written on the DOH special ("yellow") prescription form or another form currently authorized by the Dangerous Drugs Board. Hospitals keep separate dangerous drug records and secure storage.